Literature DB >> 30987923

The abiding relevance of mouse models of rare mutations to psychiatric neuroscience and therapeutics.

Joseph A Gogos1, Gregg Crabtree2, Anastasia Diamantopoulou2.   

Abstract

Studies using powerful family-based designs aided by large scale case-control studies, have been instrumental in cracking the genetic complexity of the disease, identifying rare and highly penetrant risk mutations and providing a handle on experimentally tractable model systems. Mouse models of rare mutations, paired with analysis of homologous cognitive and sensory processing deficits and state-of-the-art neuroscience methods to manipulate and record neuronal activity have started providing unprecedented insights into pathogenic mechanisms and building the foundation of a new biological framework for understanding mental illness. A number of important principles are emerging, namely that degradation of the computational mechanisms underlying the ordered activity and plasticity of both local and long-range neuronal assemblies, the building blocks necessary for stable cognition and perception, might be the inevitable consequence and the common point of convergence of the vastly heterogeneous genetic liability, manifesting as defective internally- or stimulus-driven neuronal activation patterns and triggering the constellation of schizophrenia symptoms. Animal models of rare mutations have the unique potential to help us move from "which" (gene) to "how", "where" and "when" computational regimes of neural ensembles are affected. Linking these variables should improve our understanding of how symptoms emerge and how diagnostic boundaries are established at a circuit level. Eventually, a better understanding of pathophysiological trajectories at the level of neural circuitry in mice, aided by basic human experimental biology, should guide the development of new therapeutics targeting either altered circuitry itself or the underlying biological pathways.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Animal models; Cognition; Human genetics; Neural circuits; Schizophrenia; Therapeutics

Mesh:

Year:  2019        PMID: 30987923      PMCID: PMC6790166          DOI: 10.1016/j.schres.2019.03.018

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  181 in total

1.  Cognitive performance and functional competence as predictors of community independence in schizophrenia.

Authors:  R Walter Heinrichs; Narmeen Ammari; Ashley A Miles; Stephanie McDermid Vaz
Journal:  Schizophr Bull       Date:  2008-07-30       Impact factor: 9.306

2.  Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene.

Authors:  Atsushi Takata; Bin Xu; Iuliana Ionita-Laza; J Louw Roos; Joseph A Gogos; Maria Karayiorgou
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

3.  Memory impairment in schizophrenia: a meta-analysis.

Authors:  A Aleman; R Hijman; E H de Haan; R S Kahn
Journal:  Am J Psychiatry       Date:  1999-09       Impact factor: 18.112

Review 4.  Recollection and familiarity in schizophrenia: a quantitative review.

Authors:  Laura A Libby; Andrew P Yonelinas; Charan Ranganath; J Daniel Ragland
Journal:  Biol Psychiatry       Date:  2012-12-14       Impact factor: 13.382

5.  Age-Dependent Specific Changes in Area CA2 of the Hippocampus and Social Memory Deficit in a Mouse Model of the 22q11.2 Deletion Syndrome.

Authors:  Rebecca A Piskorowski; Kaoutsar Nasrallah; Anastasia Diamantopoulou; Jun Mukai; Sami I Hassan; Steven A Siegelbaum; Joseph A Gogos; Vivien Chevaleyre
Journal:  Neuron       Date:  2016-01-06       Impact factor: 17.173

6.  Midlatency auditory event-related potentials in mice: comparison to midlatency auditory ERPs in humans.

Authors:  Daniel Umbricht; Dimitri Vyssotky; Alexander Latanov; Roger Nitsch; Riccardo Brambilla; Patrizia D'Adamo; Hans-Peter Lipp
Journal:  Brain Res       Date:  2004-09-03       Impact factor: 3.252

Review 7.  Perception measurement in clinical trials of schizophrenia: promising paradigms from CNTRICS.

Authors:  Michael F Green; Pamela D Butler; Yue Chen; Mark A Geyer; Steven Silverstein; Jonathan K Wynn; Jong H Yoon; Vance Zemon
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

8.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

9.  Adolescent Isolation Interacts With DISC1 Point Mutation to Impair Adult Social Memory and Synaptic Functions in the Hippocampus.

Authors:  Nan Li; Lin Cui; Ge Song; Li Guo; Huating Gu; Haisheng Cao; Guo-Dong Li; Yu Zhou
Journal:  Front Cell Neurosci       Date:  2018-08-02       Impact factor: 5.505

10.  Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis.

Authors:  Max Lam; Jimmy Lee; Attilio Rapisarda; Yuen Mei See; Zixu Yang; Sara-Ann Lee; Nur Amirah Abdul-Rashid; Michael Kraus; Mythily Subramaniam; Siow-Ann Chong; Richard S E Keefe
Journal:  JAMA Psychiatry       Date:  2018-09-01       Impact factor: 21.596

View more
  3 in total

1.  Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice.

Authors:  Jun Mukai; Enrico Cannavò; Gregg W Crabtree; Ziyi Sun; Anastasia Diamantopoulou; Pratibha Thakur; Chia-Yuan Chang; Yifei Cai; Stavros Lomvardas; Atsushi Takata; Bin Xu; Joseph A Gogos
Journal:  Neuron       Date:  2019-10-09       Impact factor: 17.173

2.  An in vitro model of neuronal ensembles.

Authors:  M Angeles Rabadan; Estanislao Daniel De La Cruz; Sneha B Rao; Yannan Chen; Cheng Gong; Gregg Crabtree; Bin Xu; Sander Markx; Joseph A Gogos; Rafael Yuste; Raju Tomer
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

3.  Aberrant Cortical Ensembles and Schizophrenia-like Sensory Phenotypes in Setd1a+/- Mice.

Authors:  Jordan P Hamm; Yuriy Shymkiv; Jun Mukai; Joseph A Gogos; Rafael Yuste
Journal:  Biol Psychiatry       Date:  2020-01-16       Impact factor: 13.382

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.